Aduro BioTech, J&J deal

Aduro granted Johnson & Johnson's Janssen Biotech Inc. subsidiary exclusive, worldwide rights to lung cancer products based on Aduro's live-attenuated double-deleted Listeria monocytogenes (LADD) immunotherapy platform. Aduro declined to disclose details on the number of products or development status. Aduro received $30 million up front and is eligible for up to $817 in milestones, plus high single- to double-digit tiered royalties. Janssen is responsible for R&D, manufacturing and regulatory and commercial activities. The deal originated at J&J's California Innovation Center. ...